1 Department of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
2 Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Otolaryngol Head Neck Surg. 2019 May;160(5):822-828. doi: 10.1177/0194599819829743. Epub 2019 Feb 12.
The cost-effectiveness of endovascular embolization (EE) for intractable epistaxis has been questioned, especially as endoscopic surgical techniques have become standard of care at many institutions. Our objectives were to review the safety profile and effectiveness of EE for epistaxis.
Retrospective case series.
Tertiary care hospital.
There were 54 patients and 64 unique encounters. Patients were 66.7% male, with a mean age of 64.5 years. Bleeding disorders were present in 18.8%, hypertension was present in 71.7%, and 61.1% were on anticoagulant/platelet drugs.
Charts of patients undergoing EE for epistaxis between 2005 and 2015 were retrospectively reviewed.
The immediate bleeding control rate was 92.6%. Three patients died within 1 week of EE and were excluded from further analysis. Overall, 64.7% of the remaining patients had no further episodes of epistaxis. Thirteen patients (25.4%) rebled within 1 week, 11 of whom required repeat EE or operative control. Five patients (9.8%) rebled more than 1 week following the procedure with 4 requiring repeat EE or operative control. The major complication rate was 7.4% and included transient stroke, diplopia, facial skin necrosis, and extraperitoneal hemorrhage.
While the immediate success rate of EE for epistaxis was comparable to the literature, the overall short- and long-term rebleed rate was high in this selected population. The results suggest that patients who are referred for EE represent a high-risk group with increased risk of repeat hemorrhage and morbidity. Patients who undergo EE for epistaxis should be carefully monitored for complications, including repeat hemorrhage.
腔内栓塞(EE)治疗难治性鼻出血的成本效益一直受到质疑,尤其是在许多机构内镜手术技术已成为标准治疗方法的情况下。我们的目的是回顾 EE 治疗鼻出血的安全性和有效性。
回顾性病例系列。
三级保健医院。
共有 54 名患者和 64 次就诊。患者中男性占 66.7%,平均年龄为 64.5 岁。18.8%存在出血性疾病,71.7%存在高血压,61.1%正在服用抗凝/血小板药物。
回顾性分析 2005 年至 2015 年间接受 EE 治疗鼻出血的患者的病历。
即刻止血率为 92.6%。3 名患者在 EE 后 1 周内死亡,被排除在进一步分析之外。总的来说,64.7%的其余患者没有再次出现鼻出血。13 名患者(25.4%)在 1 周内再次出血,其中 11 名需要重复 EE 或手术控制。5 名患者(9.8%)在手术后超过 1 周再次出血,其中 4 名需要重复 EE 或手术控制。主要并发症发生率为 7.4%,包括短暂性中风、复视、面部皮肤坏死和腹膜外出血。
虽然 EE 治疗鼻出血的即刻成功率与文献报道相当,但在这一选定人群中,短期和长期再出血率较高。结果表明,接受 EE 治疗的患者代表了一个高风险群体,再次出血和发病的风险增加。接受 EE 治疗鼻出血的患者应密切监测并发症,包括再次出血。